Dec 2022
Sole Financial Adviser
€ 12.0 million
Convertible Note Issuance
GenSight Biologics S.A.
Sole Financial Adviser
Van Lanschot Kempen acted as Sole Financial Adviser to GenSight Biologics S.A. in securing €12.0 million financing through the issuance of convertible notes to support the launch of LUMEVOQ® in Europe
Transaction highlights
- The €12.0 million issuance of convertible notes will enable GenSight Biologics to support the development of its pipeline and, in particular, the preparation of the marketing of LUMEVOQ® in Europe
- In November 2022, Van Lanschot Kempen acted as the Sole Financial Adviser to Gensight Biologics on the €35.0 million conditional loan by the European Investment Bank (EIB)
- The issuance of these convertible bonds, will allow GenSight Biologics to draw down the first €8.0 million tranche of the EIB credit facility
- In difficult market circumstances, Van Lanschot Kempen has been able to successfully assist its client with an innovative financing solution. This transaction underpins our ambition to serve our clients with a wide variety of tailormade financing structures
- The successful completion of this financing marks the nineth transaction for Van Lanschot Kempen’s Debt Advisory team in the last twelve months.
Company description
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), has been submitted for marketing approval in Europe for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
Background Van Lanschot Kempen Life Sciences & Healthcare
In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:
- Joint Global Coordinator and Joint Bookrunner in the SEK 416 million Capital Increase by Hansa Biopharma
- Sole Financial Adviser in SynAct Pharma’s acquisition of TXP Pharma and Joint Global Coordinator & Joint Bookrunner in SynAct Pharma’s SEK 80m PIPE
- Joint Bookrunner in the SEK 200 million Accelerated Bookbuild Offering by Vicore Pharma
- Joint Bookrunner in the SEK 148 million Fully Guaranteed Rights Issue by Biovica
- Sole Financial Adviser to GenSight Biologics in securing a €35 million credit facility from the European Investment Bank
- Joint Global Coordinator & Joint Bookrunner in the SEK 170 million Accelerated Bookbuild Offering by Xbrane Biopharma
- Co-Lead Manager in the DKK 786 million Capital Increase by Zealand Pharma
- Financial Advisor in the sale of Sanquin Reagents by Sanquin Health Solutions to Gilde Healthcare
- Financial Advisor in the up to SEK 250 million (convertible) debt financing by Mendus
- Joint Global Coordinator in the SEK 299 million Directed Share Issue via PIPE by BioInvent
- Sole Global Coordinator in the SEK 200 million financing consisting of a SEK 150 million Directed Share Issue via PIPE and a SEK 50 million Fully Guaranteed Rights Issue by Abliva
- Joint Global Coordinator & Joint Bookrunner in the SEK 150 million Fully Guaranteed Rights Issue by SynAct Pharma
- Financial adviser in the spin-out and Capital Increase of InnoSIGN
- Co-Manager in the USD 806 million Capital Increase by argenx
- Sole Block Placing Agent in the placement of 1.4 and 1.3 million Molecular Partners shares